These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37537626)

  • 1. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
    Liu X; Zhao J; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
    González Barca E
    Front Immunol; 2022; 13():909008. PubMed ID: 35928819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibodies in indolent B-cell lymphomas.
    Radhakrishnan VS; Davies AJ
    Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
    J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
    Qu Z; Goldenberg DM; Cardillo TM; Shi V; Hansen HJ; Chang CH
    Blood; 2008 Feb; 111(4):2211-9. PubMed ID: 18025153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on bi-specific monoclonal antibodies for blood cancers.
    Shouse G
    Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
    Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
    Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
    Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
    J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
    Amhaz G; Bazarbachi A; El-Cheikh J
    Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
    Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
    Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mosunetuzumab: First Approval.
    Kang C
    Drugs; 2022 Jul; 82(11):1229-1234. PubMed ID: 35947358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Human B-Cell Lymphomas Using Minicircle DNA Vector Expressing Anti-CD3/CD20 in a Mouse Model.
    Pang X; Ma F; Zhang P; Zhong Y; Zhang J; Wang T; Zheng G; Hou X; Zhao J; He C; Chen ZY
    Hum Gene Ther; 2017 Feb; 28(2):216-225. PubMed ID: 27802782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
    Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
    Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
    [No Abstract]   [Full Text] [Related]  

  • 16. Glofitamab CD20-TCB bispecific antibody.
    Minson A; Dickinson M
    Leuk Lymphoma; 2021 Dec; 62(13):3098-3108. PubMed ID: 34263696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
    Schuster SJ
    Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
    Lu CY; Chen GJ; Tai PH; Yang YC; Hsu YS; Chang M; Hsu CL
    Biochem Biophys Res Commun; 2016 May; 473(4):808-813. PubMed ID: 27040766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.
    Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Chang CH
    Blood; 2009 Jun; 113(24):6161-71. PubMed ID: 19372261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting.
    Sun H; Xing H; Han L; Song Y; Jiang Z; Liu Y; Yu J
    Expert Opin Biol Ther; 2024 May; 24(5):321-326. PubMed ID: 38717336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.